The prescribing decision
An assessment comes before a prescription.
A prescription orders medicine; it comes from the person treating you, known as your clinician. Ask what the decision is based on, and what other care could address the concern.
Start with what is being treated
Ask what the clinician thinks is causing the concern. Then ask what evidence supports each option and what would count as a useful change.
A visit can end with more questions, a test or a plan to see another health professional. Keep the question about care open.
Approval and making medicine are separate checks
A prescription does not mean approval
Medicine reviews by the Food and Drug Administration (FDA) concern specific uses.
As of September 2026, it had approved no BPC-157 medicine for any use in the US. [A]
A clinician’s order does not give a product that approval.
Compounding is a separate question
Compounding is the making or mixing of medicine for a patient’s needs instead of using a finished factory product.
As of September 2026, compounded medicines were not FDA-approved, and the agency did not check their benefit, quality or safety before marketing. [B]
The fact that a pharmacy can compound some medicines does not settle whether it can use a particular ingredient.
Trace the ingredient rules
The law limits which ingredients a pharmacy can use
As of September 2026, federal law limited the raw ingredients a pharmacy could use to make medicine for an individual patient. [C]
The ingredient must meet any quality rules set for it in an official drug reference book. If the book has no entry, it must be in an FDA-approved medicine. When neither route applies, the ingredient must appear on FDA’s list of extra ingredients allowed for this pharmacy work.
FDA’s review found no entry for BPC-157 in those reference books. It was not an ingredient in an approved medicine and was not on the extra-ingredient list. [A]
HHS proposed in its October 30, 2026 draft to hold off on enforcement for BPC-157 prepared on a patient’s prescription by state-licensed pharmacies and licensed doctors that meet its conditions.
A withdrawn request is not permission
In the FDA record checked on September 28, 2026, the requests to use BPC-157 had been taken back. The page’s update date was April 22, 2026; it did not say when those requests were taken back. [D]
The groups that wanted pharmacies to use BPC-157 took back their requests. This did not give approval or meet the ingredient rules.
In July 2026, FDA staff recommended keeping BPC-157 off the ingredient list. That was a recommendation, not a final decision. HHS reported a July 2026 committee vote in favor of adding BPC-157 in the draft dated October 30, 2026. [A]
The committee’s role is advisory; a vote from it leaves the law unchanged. To change the list, FDA must write a new rule through a process that lets the public comment.
Page notes
[A] FDA’s BPC-157 briefing and proposed recommendation
[B] FDA explanation of made-to-order medicines
[C] FDA’s ingredient rules for medicine made for individual patients